Focused On-demand Library for Protein Mdm4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O15151

UPID:

MDM4_HUMAN

Alternative names:

Double minute 4 protein; Mdm2-like p53-binding protein; Protein Mdmx; p53-binding protein Mdm4

Alternative UPACC:

O15151; Q2M2Y2; Q32SL2; Q6GS18; Q8IV83

Background:

Protein Mdm4, also known as Double minute 4 protein, Mdm2-like p53-binding protein, and p53-binding protein Mdm4, plays a crucial role in cellular processes. It is instrumental in regulating TP53, a key tumor suppressor gene, by inhibiting its cell cycle arrest and apoptosis functions. Mdm4's interaction with MDM2 further influences TP53's stability and activity, showcasing its pivotal role in cell cycle regulation and apoptosis.

Therapeutic significance:

Given its involvement in Bone marrow failure syndrome 6, characterized by hematopoietic defects and increased cancer susceptibility, Mdm4 presents a significant target for therapeutic intervention. Understanding the role of Protein Mdm4 could open doors to potential therapeutic strategies, especially in conditions where TP53 regulation is compromised.